Latest Headlines

Latest Headlines

China's Sihuan marks first U.S. patient enrollment of PhI oncology candidate

Sihuan Pharmaceutical said it has successfully enrolled the first patient in the United States for its Phase I clinical trial of Pirotinib developed by Shandong XuanZhu Pharma, a wholly owned subsidiary, working with Covance on preparation and initiation.

HK's Sihuan in partnership with Covance on drug development

Hong Kong-listed Sihuan Pharmaceutical said it has joined hands with U.S.-based Covance to develop a drug pipeline aimed at China and U.S. approvals.

UPDATED: $6B Covance buyout puts LabCorp in the CRO biz

LabCorp is diversifying. The big diagnostics player has swooped in to buy the contract research organization Covance for $6.1 billion in cash and stock, confident that a combination of its expertise with Covance's approach to contract drug development will make for a successful merger.

Covance taps NeoGenomics for cancer trial diagnostics

Global CRO Covance has struck up a deal to expand its diagnostics capabilities in oncology trials, partnering with NeoGenomics to bolster its anatomic pathology and specialty lab testing.

Covance partners up for biologics safety testing

As regulators the world over clamp down on biologics development, Covance has struck up a partnership with Pathoquest to offer next-generation sequencing-based tests for biotherapeutics.

Covance ups expectations thanks to booming lab biz

Global CRO Covance rode a spike in demand for its late-stage services to a solid third quarter, increasing its revenue guidance and counting on a bump in business to light the way for Q4.

Covance launches lab management service to cut study costs

Drug developers look to external labs to do all manners of tests, but they can easily get stretched too thin when trying to manage myriad vendors. Covance is kicking off an external lab management offering, promising to save its clients as much as 65% in oversight costs.

Covance teams with Indiana U. for early trials

CRO giant Covance has signed a deal with the Indiana University School of Medicine, bringing more Phase I studies to the school's on-site clinical research unit and giving Covance a broader footprint for early trials.

Report: Big CROs soared 10% last year

Despite concerns about slashed R&D budgets, overexpansion and consolidation, the titans of the CRO business are still posting double-digit growth, clocking $13.6 billion in 2012, according to a report.

How can early-phase CROs stay afloat in a changing market?

They don't make compounds like the used to--or at least at the same rate. And with fewer and fewer early-stage molecules moving through pipelines, some discovery-focused CROs have been left in the lurch.